Defining Robust Predictors of Chemotherapy Related Cardiotoxicity
Launched by UNIVERSITY COLLEGE, LONDON · Dec 1, 2021
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how to predict heart problems that can happen as a side effect of chemotherapy in patients with certain types of gastrointestinal cancers, like stomach or colon cancer. The researchers want to understand more about who is at risk for these heart issues while receiving a specific type of chemotherapy called fluoropyrimidine.
To participate in this study, individuals need to be over 18 years old and have agreed to receive fluoropyrimidine chemotherapy for their gastrointestinal cancer. The trial is currently recruiting participants of all genders who meet these criteria. Those who join the study can expect to be monitored closely for heart health during their treatment, which can help doctors better understand and potentially prevent these side effects in the future. This research aims to improve the care and safety of patients undergoing chemotherapy for gastrointestinal cancers.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age \>18
- • Consented to receive fluoropyrimidine chemotherapy for GI malignancies (gastro-oesophageal, colorectal, pancreatic)
- • Capacity to provide consent
- Exclusion Criteria:
- • Age \<18
- • Lacking capacity to consent
About University College, London
University College London (UCL) is a leading global research institution renowned for its commitment to advancing healthcare through innovative clinical trials. As a prominent sponsor of clinical research, UCL leverages its multidisciplinary expertise and state-of-the-art facilities to conduct rigorous investigations aimed at improving patient outcomes and addressing pressing medical challenges. The institution fosters collaboration among researchers, healthcare professionals, and industry partners, ensuring that its trials adhere to the highest ethical standards and regulatory guidelines. UCL's dedication to translating scientific discoveries into practical applications underscores its role as a vital contributor to the advancement of medical science and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
London, , United Kingdom
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials